Status In progress
Process STA Review
ID number 1072

Project Team

Project lead Thomas Feist

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
02 November 2017 Committee meeting: 1
17 July 2017 Invitation to participate
01 December 2016 Following an initial review of the company’s submission for the appraisal Breast cancer (locally advanced, metastatic) - eribulin (after chemotherapy) [ID964] by the Evidence Review Group (ERG), it was noted that the submission considered the population for this scope in terms of two distinct subgroups and that this considerably increased the complexity of the ERG’s task. In order to allow the ERG to provide a thorough critique of the evidence in support of both subgroups, it was agreed that the ERG would provide reports on each of the two subgroups separately. Consequently the ERG first provided a report focusing on the clinical and cost effectiveness of eribulin in ‘patients with locally advanced or metastatic breast cancer whose disease has progressed after at least two prior chemotherapeutic regimens for advanced disease which includes capecitabine (if indicated)’. This was considered by the appraisal committee at its meeting on 20 September 2016. An ERG report on the subgroup of ‘people with locally advanced or metastatic breast cancer whose disease has progressed after one prior chemotherapy regimen in the advanced setting’ will be produced subsequently and this will be considered by the committee at a later date. The timelines will be confirmed shortly. Therefore 2 separate pieces of guidance will be produced for this appraisal, one after the other. Updated versions of the scope for these appraisals are available on the NICE website. The changes are shown in in red and only relate to the population under consideration. No changes have been made to other aspects of the scope. For further details, please go to www.nice.org.uk/guidance/indevelopment/gid-ta10030/documents
06 September 2016 Draft scope documents
06 September 2016 An ERG report on the subgroup of ‘people with locally advanced or metastatic breast cancer whose disease has progressed after one prior chemotherapy regimen in the advanced setting’ will be produced and this will be considered by the committee at a later date. We will confirm the timelines for this shortly

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance